KEA 0447Alternative Names: KRP-EPA-605
Latest Information Update: 08 Apr 2016
At a glance
- Originator Kissei Pharmaceutical; Kyorin Pharmaceutical
- Class Urologics
- Mechanism of Action Prostaglandin-E EP1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 17 Oct 2013 Phase-I clinical trials in Overactive bladder in Japan (unspecified route)